Request Trial
jackie-7
26 November 2020Muireann Bolger

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
UK firm hires head of IP with commercial and technical nous
8 September 2026   With technical specialisms including nucleic acid technologies, biological therapeutics and vaccines, and diagnostics and biological assays, the new hire adds a life sciences patent specialism to the firm’s growing IP practice.
Pharma
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
7 September 2026   A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.
Regulation & Industry
G 1/25: EPO settles controversial patent description question
4 September 2026   Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

UK firm hires head of IP with commercial and technical nous
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
G 1/25: EPO settles controversial patent description question
California votes for law to restrict use of genAI by lawyers
10x Genomics wins latest round in Parse patent dispute
Sun Pharma import ban back in force after Squires intervention
White & Case life sciences co-leader moves firms
‘Busiest’ US district patent judge swaps bench for private practice